2021 Conferences Archives

May 25, 2022

ASH 2021: Dr. Kerry Rogers on the Addition of Ianalumab (VAY736) to Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL)

Discussion of a new monoclonal antibody, ianalumab (previously known as VAY736), targeting the B-cell activating factor (BAFF) receptor. We refer to the compound as VAY736 for consistency with the interview and abstract for this article.

April 13, 2022

ASH 2021: Dr. Constantine Tam on BTK Inhibitor TG-1701 for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

At the American Society of Hematology (ASH) 2021, Dr. Alan Skarbnick, Director of the CLL program at Novant Health Cancer Institute in Charlotte, NC, interviewed Dr. Constantine Tam, a hematologist at the Peter McCallum Cancer Center in Melbourne, Australia. They discussed the results of a phase 1 clinical trial

April 8, 2022

ASH 2021: Dr. Constantine Tam on Zanubrutinib in Combination with Venetoclax for Patients with Deletion 17p

CLL and SLL patients with deletion 17p do not respond well to chemoimmunotherapy. But new targeted therapies may help. Zanubrutinib is a next-generation BTK inhibitor being tested in combination with venetoclax for treating patients with deletion 17p. Results from a Phase III trial of this combination were presented at

March 30, 2022

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a

March 25, 2022

ASH 2021: Prevalence and survival of low count monoclonal B-cell lymphocytosis (LC-MBL): A screening study of 8,297 individuals from the Mayo Clinic Biobank

Dr. Susan Slager and colleagues presented this research at the American Society of Hematology Annual Meeting, which was held in December 2021 (ASH 2021)

March 16, 2022

A CLL Trial in Progress for Those Who Relapsed After Venetoclax Plus Obinutuzumab

Here we review ReVenG, a phase 2 study of venetoclax plus obinutuzumab retreatment (“second time”) in patients with relapsed chronic lymphocytic leukemia (CLL) (ClinicalTrials.gov Identifier: NCT04895436) that fits that category. It was presented at ASH 2021 by Dr. Matthew Davids.

March 16, 2022

ASH 2021: Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Acalabrutinib (A) and ibrutinib (I) are both highly effective Bruton tyrosine kinase (BTK) inhibitors approved for the treatment of chronic lymphocytic leukemia (CLL) and given as continuous treatments until disease progression or unacceptable toxicity.

March 10, 2022

ASH 2021: Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US)

There have been many advances in chronic lymphocytic leukemia small lymphocytic lymphoma (CLL/SLL) treatments over the past decade, with several potent novel agents targeting molecular pathways within CLL cells receiving FDA approval.

2021 Conferences

ASH 2021: Dr. Kerry Rogers on the Addition of Ianalumab (VAY736) to Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL)

ASH 2021: Dr. Constantine Tam on BTK Inhibitor TG-1701 for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

ASH 2021: Dr. Constantine Tam on Zanubrutinib in Combination with Venetoclax for Patients with Deletion 17p

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

ASH 2021: Prevalence and survival of low count monoclonal B-cell lymphocytosis (LC-MBL): A screening study of 8,297 individuals from the Mayo Clinic Biobank

A CLL Trial in Progress for Those Who Relapsed After Venetoclax Plus Obinutuzumab

ASH 2021: Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

ASH 2021: Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT